Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Medtronic stock | $127.3

Own Medtronic stock in just a few minutes.

Medtronic plc is a medical devices business based in the US. Medtronic shares (MDT) are listed on the NYSE and all prices are listed in US Dollars. Medtronic employs 90,000 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Medtronic

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MDT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Medtronic share price

Use our graph to track the performance of MDT stocks over time.

Medtronic shares at a glance

Information last updated 2021-05-07.
Latest market close$127.30
52-week range$86.32 - $132.30
50-day moving average $123.77
200-day moving average $116.50
Wall St. target price$134.31
PE ratio 56.0956
Dividend yield $2.28 (1.79%)
Earnings per share (TTM) $2.26

Buy Medtronic shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Medtronic stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Medtronic price performance over time

Historical closes compared with the close of $127.3 from 2021-05-06

1 week (2021-05-05) 0.24%
1 month (2021-04-16) 1.10%
3 months (2021-02-16) 6.37%
6 months (2020-11-16) 14.05%
1 year (2020-05-15) 35.58%
2 years (2019-05-16) 44.48%
3 years (2018-05-16) 48.80%
5 years (2016-05-16) 55.45%

Is Medtronic under- or over-valued?

Valuing Medtronic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medtronic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Medtronic's P/E ratio

Medtronic's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 56x. In other words, Medtronic shares trade at around 56x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Medtronic's PEG ratio

Medtronic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.8925. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medtronic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Medtronic's EBITDA

Medtronic's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.3 billion.

The EBITDA is a measure of a Medtronic's overall financial performance and is widely used to measure a its profitability.

Medtronic financials

Revenue TTM $27.9 billion
Operating margin TTM 13.67%
Gross profit TTM $19.6 billion
Return on assets TTM 2.51%
Return on equity TTM 5.97%
Profit margin 10.97%
Book value $37.67
Market capitalisation $170.8 billion

TTM: trailing 12 months

Shorting Medtronic shares

There are currently 11.7 million Medtronic shares held short by investors – that's known as Medtronic's "short interest". This figure is 55.3% up from 7.5 million last month.

There are a few different ways that this level of interest in shorting Medtronic shares can be evaluated.

Medtronic's "short interest ratio" (SIR)

Medtronic's "short interest ratio" (SIR) is the quantity of Medtronic shares currently shorted divided by the average quantity of Medtronic shares traded daily (recently around 5.0 million). Medtronic's SIR currently stands at 2.32. In other words for every 100,000 Medtronic shares traded daily on the market, roughly 2320 shares are currently held short.

However Medtronic's short interest can also be evaluated against the total number of Medtronic shares, or, against the total number of tradable Medtronic shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Medtronic's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Medtronic shares in existence, roughly 10 shares are currently held short) or 0.0087% of the tradable shares (for every 100,000 tradable Medtronic shares, roughly 9 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Medtronic.

Find out more about how you can short Medtronic stock.

Medtronic's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Medtronic.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Medtronic's total ESG risk score

Total ESG risk: 26.86

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Medtronic's overall score of 26.86 (as at 12/31/2018) is nothing to write home about – landing it in it in the 41st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Medtronic is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Medtronic's environmental score

Environmental score: 4.07/100

Medtronic's environmental score of 4.07 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Medtronic's social score

Social score: 15.28/100

Medtronic's social score of 15.28 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Medtronic's governance score

Governance score: 9/100

Medtronic's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Medtronic is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Medtronic's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Medtronic scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Medtronic hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Medtronic plc was last rated for ESG on: 2019-01-01.

Total ESG score 26.86
Total ESG percentile 40.62
Environmental score 4.07
Environmental score percentile 5
Social score 15.28
Social score percentile 5
Governance score 9
Governance score percentile 5
Level of controversy 3

Medtronic share dividends

66%

Dividend payout ratio: 66.1% of net profits

Recently Medtronic has paid out, on average, around 66.1% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.82% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Medtronic shareholders could enjoy a 1.82% return on their shares, in the form of dividend payments. In Medtronic's case, that would currently equate to about $2.28 per share.

Medtronic's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Medtronic's most recent dividend payout was on 15 April 2021. The latest dividend was paid out to all shareholders who bought their shares by 24 March 2021 (the "ex-dividend date").

Have Medtronic's shares ever split?

Medtronic's shares were split on a 2:1 basis on 26 September 1999. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Medtronic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Medtronic shares which in turn could have impacted Medtronic's share price.

Medtronic share price volatility

Over the last 12 months, Medtronic's shares have ranged in value from as little as $86.3189 up to $132.3. A popular way to gauge a stock's volatility is its "beta".

MDT.US volatility(beta: 0.8)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Medtronic's is 0.8. This would suggest that Medtronic's shares are less volatile than average (for this exchange).

Medtronic overview

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Minimally Invasive Therapies Group segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, and gynecology products; electrosurgical hardware and instruments, and mesh fixation devices; and gastrointestinal, inhalation therapy, and renal care solutions. The Restorative Therapies Group segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; colorectal surgeons; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site